On November 27, GW Pharmaceuticals (GWPH) presented its fourth-quarter and fiscal 2018 financial results. GW Pharmaceuticals’ net revenues in fiscal 2018 were $12.74, which represents ~15.75% YoY (year-over-year) growth. To learn more, read Here Are Some of GW Pharmaceuticals’ Key Growth Drivers.
INSYS Therapeutics (INSY) reported revenues of $18.35 million in the third quarter, which represents an ~40.18% YoY decline. Cara Therapeutics (CARA) reported revenues of $5.03 million. Cara Therapeutics didn’t report revenues in the third quarter of 2017. To learn more, read Cara Therapeutics: A Financial Overview in January.
In the fourth quarter, INSYS Therapeutics and Cara Therapeutics are expected to generate revenues of $18.16 million and $2.67 million, respectively.
Analysts expect that INSYS Therapeutics and Cara Therapeutics’ net revenues in fiscal 2018 will be ~$83.95 million and $10.60 million, respectively, compared to reported revenues of $140.69 million and $0.91 million in fiscal 2017.
In 2019 and 2020, analysts expect Cara Therapeutics to generate net revenues of $11.21 million and $19.11 million, respectively, which represents ~5.73% and ~70.49% YoY growth.
Analysts expect INSYS Therapeutics’ net revenues in 2019 and 2020 to be ~$75.39 million and $102.28 million, which represents an ~10.20% YoY decline and ~35.67% YoY growth.
Cara Therapeutics, INSYS Therapeutics, and GW Pharmaceuticals revenue growth could boost the ETFMG Alternative Harvest ETF’s (MJ) share prices. Cara Therapeutics, INSYS Therapeutics, and GW Pharmaceuticals account for ~1.52%, ~1.64%, and 5.95% of MJ’s total portfolio holding.